By nearly unanimous consent artificial intelligence reached an inflection point for pharma marketers in 2023. The question of how best to take advantage of this new tool to support brands and help patients, though, remains to be seen.
Tag Archive for: 2024
Jesse Mendelsohn, senior VP at Model N, shares two key predictions for pharma this year.
Iovance’s lifileucel for advanced melanoma and Madrigal’s resmetirom for nonalcoholic steatohepatitis are just a couple of the key decisions on the FDA’s docket this quarter.
Part VI: Leaders in healthcare marketing and communications share their thoughts on what excites them about the year ahead.
